FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2807483406> ?p ?o ?g. }

• W2807483406 endingPage "126" @default.
• W2807483406 startingPage "116" @default.
• W2807483406 abstract "Purpose To compare patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer. Methods and Materials The prospective, population-based Comparative Effectiveness Analysis of Surgery and Radiation study enrolled men with localized prostate cancer in 2011 to 2012. The 26-item Expanded Prostate Cancer Index Composite measured patient-reported disease-specific function at baseline and at 6, 12, and 36 months. Higher domain scores indicate better function. Minimal clinically important difference was defined as 6 for urinary incontinence, 5 for urinary irritative function, 4 for bowel function, 12 for sexual function, and 4 for hormonal function. Multivariable linear and logistic regression models were fit to estimate the effect of treatment on patient-reported outcomes. Results Five-hundred seventy-eight men received EBRT and 109 received EB-LDR. Median patient age was 69 years, and 70% had intermediate- or high-risk disease. Men in the EB-LDR group were younger (P < .001) and less likely to receive androgen deprivation therapy (P < .001). Baseline urinary, bowel, sexual, and hormonal function was similar between treatment groups (P > .05). On multivariable analyses, men receiving EB-LDR reported worse urinary irritative function at 6 months (adjusted mean difference [AMD] −14.4, P < .001), 12 months (AMD −12.9, P < .001), and 36 months (AMD −4.7, P = .034) than men receiving EBRT. At 12 months, men receiving EB-LDR reported worse bowel function (AMD −5.8, P = .002), but these differences were not seen at 36 months. There were no significant differences in sexual or hormone function between treatment groups. Conclusions Men treated with EB-LDR report worse bowel function at 1 year and worse urinary irritative function through 3 years compared with men treated with EBRT alone. These side effect profiles should be discussed with patients when considering EB-LDR versus EBRT treatment. To compare patient-reported disease-specific functional outcomes after external beam radiation therapy (EBRT) and EBRT combined with low-dose-rate brachytherapy prostate boost (EB-LDR) among men with localized prostate cancer. The prospective, population-based Comparative Effectiveness Analysis of Surgery and Radiation study enrolled men with localized prostate cancer in 2011 to 2012. The 26-item Expanded Prostate Cancer Index Composite measured patient-reported disease-specific function at baseline and at 6, 12, and 36 months. Higher domain scores indicate better function. Minimal clinically important difference was defined as 6 for urinary incontinence, 5 for urinary irritative function, 4 for bowel function, 12 for sexual function, and 4 for hormonal function. Multivariable linear and logistic regression models were fit to estimate the effect of treatment on patient-reported outcomes. Five-hundred seventy-eight men received EBRT and 109 received EB-LDR. Median patient age was 69 years, and 70% had intermediate- or high-risk disease. Men in the EB-LDR group were younger (P < .001) and less likely to receive androgen deprivation therapy (P < .001). Baseline urinary, bowel, sexual, and hormonal function was similar between treatment groups (P > .05). On multivariable analyses, men receiving EB-LDR reported worse urinary irritative function at 6 months (adjusted mean difference [AMD] −14.4, P < .001), 12 months (AMD −12.9, P < .001), and 36 months (AMD −4.7, P = .034) than men receiving EBRT. At 12 months, men receiving EB-LDR reported worse bowel function (AMD −5.8, P = .002), but these differences were not seen at 36 months. There were no significant differences in sexual or hormone function between treatment groups. Men treated with EB-LDR report worse bowel function at 1 year and worse urinary irritative function through 3 years compared with men treated with EBRT alone. These side effect profiles should be discussed with patients when considering EB-LDR versus EBRT treatment." @default.
• W2807483406 created "2018-06-13" @default.
• W2807483406 creator A5000035861 @default.
• W2807483406 creator A5011837566 @default.
• W2807483406 creator A5021843135 @default.
• W2807483406 creator A5021979132 @default.
• W2807483406 creator A5048328069 @default.
• W2807483406 creator A5059518368 @default.
• W2807483406 creator A5062800125 @default.
• W2807483406 creator A5064915506 @default.
• W2807483406 creator A5065202863 @default.
• W2807483406 creator A5066279767 @default.
• W2807483406 creator A5068903584 @default.
• W2807483406 creator A5071060478 @default.
• W2807483406 creator A5072281075 @default.
• W2807483406 creator A5073284312 @default.
• W2807483406 creator A5078458765 @default.
• W2807483406 creator A5086007942 @default.
• W2807483406 creator A5086528283 @default.
• W2807483406 creator A5087581630 @default.
• W2807483406 creator A5090789371 @default.
• W2807483406 date "2018-09-01" @default.
• W2807483406 modified "2023-10-16" @default.
• W2807483406 title "Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer" @default.
• W2807483406 cites W1494104030 @default.
• W2807483406 cites W1587527216 @default.
• W2807483406 cites W1977734707 @default.
• W2807483406 cites W2015216877 @default.
• W2807483406 cites W2017622807 @default.
• W2807483406 cites W2028742034 @default.
• W2807483406 cites W2038782312 @default.
• W2807483406 cites W2040103703 @default.
• W2807483406 cites W2053555954 @default.
• W2807483406 cites W2062313368 @default.
• W2807483406 cites W2072222375 @default.
• W2807483406 cites W2083445933 @default.
• W2807483406 cites W2101972593 @default.
• W2807483406 cites W2108818539 @default.
• W2807483406 cites W2137282952 @default.
• W2807483406 cites W2143656101 @default.
• W2807483406 cites W2153570331 @default.
• W2807483406 cites W2159782649 @default.
• W2807483406 cites W2163954169 @default.
• W2807483406 cites W2319995462 @default.
• W2807483406 cites W2329771424 @default.
• W2807483406 cites W2462672144 @default.
• W2807483406 cites W2520448081 @default.
• W2807483406 cites W2553678345 @default.
• W2807483406 cites W2569728867 @default.
• W2807483406 cites W2589714204 @default.
• W2807483406 cites W2602775013 @default.
• W2807483406 cites W2603592198 @default.
• W2807483406 doi "https://doi.org/10.1016/j.ijrobp.2018.05.043" @default.
• W2807483406 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7492102" @default.
• W2807483406 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30102188" @default.
• W2807483406 hasPublicationYear "2018" @default.
• W2807483406 type Work @default.
• W2807483406 sameAs 2807483406 @default.
• W2807483406 citedByCount "10" @default.
• W2807483406 countsByYear W28074834062019 @default.
• W2807483406 countsByYear W28074834062020 @default.
• W2807483406 countsByYear W28074834062021 @default.
• W2807483406 countsByYear W28074834062022 @default.
• W2807483406 countsByYear W28074834062023 @default.
• W2807483406 crossrefType "journal-article" @default.
• W2807483406 hasAuthorship W2807483406A5000035861 @default.
• W2807483406 hasAuthorship W2807483406A5011837566 @default.
• W2807483406 hasAuthorship W2807483406A5021843135 @default.
• W2807483406 hasAuthorship W2807483406A5021979132 @default.
• W2807483406 hasAuthorship W2807483406A5048328069 @default.
• W2807483406 hasAuthorship W2807483406A5059518368 @default.
• W2807483406 hasAuthorship W2807483406A5062800125 @default.
• W2807483406 hasAuthorship W2807483406A5064915506 @default.
• W2807483406 hasAuthorship W2807483406A5065202863 @default.
• W2807483406 hasAuthorship W2807483406A5066279767 @default.
• W2807483406 hasAuthorship W2807483406A5068903584 @default.
• W2807483406 hasAuthorship W2807483406A5071060478 @default.
• W2807483406 hasAuthorship W2807483406A5072281075 @default.
• W2807483406 hasAuthorship W2807483406A5073284312 @default.
• W2807483406 hasAuthorship W2807483406A5078458765 @default.
• W2807483406 hasAuthorship W2807483406A5086007942 @default.
• W2807483406 hasAuthorship W2807483406A5086528283 @default.
• W2807483406 hasAuthorship W2807483406A5087581630 @default.
• W2807483406 hasAuthorship W2807483406A5090789371 @default.
• W2807483406 hasBestOaLocation W28074834062 @default.
• W2807483406 hasConcept C121608353 @default.
• W2807483406 hasConcept C126322002 @default.
• W2807483406 hasConcept C126894567 @default.
• W2807483406 hasConcept C188816634 @default.
• W2807483406 hasConcept C2775871022 @default.
• W2807483406 hasConcept C2775908122 @default.
• W2807483406 hasConcept C2776235491 @default.
• W2807483406 hasConcept C2777416452 @default.
• W2807483406 hasConcept C2777899217 @default.
• W2807483406 hasConcept C2778311097 @default.
• W2807483406 hasConcept C2780192828 @default.
• W2807483406 hasConcept C2908647359 @default.
• W2807483406 hasConcept C509974204 @default.

• next